Navigation Links
GeoVax to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Date:8/26/2009

ATLANTA, Aug. 26 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a company overview at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 4:30 p.m. ET at the New York Palace Hotel in New York.

To access the live webcast of the presentation, please visit the GeoVax website at http://www.geovax.com, or http://www.wsw.com/webcast/rrshq15/govx.ob. Please connect to the website at least 15 minutes prior to the presentation to allow for any necessary software downloads. An archived replay will be available on the Company's site for 90 days following the live presentation.

Dr. McNally will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for its upcoming therapeutic human vaccine trials. Management also plans to meet one-on-one with current and prospective GeoVax investors, analysts and other potential Company partners.

"The Rodman Conference offers GeoVax an outstanding platform in which to share its milestone accomplishments related to our promising HIV-1/AIDS vaccines and plans for therapeutic human trials with the investment community. We remain devoted to finding a prevention and cure for AIDS while simultaneously managing our costs," stated Dr. McNally.

Rodman & Renshaw, LLC, a subsidiary of Rodman
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. GeoVax to Present at the BIO CEO & Investor Conference 2009
10. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
11. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... Inc. (Nasdaq: IDEV ) today announced that ... Food and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a ... only product approved by the FDA for therapy ... the,urinary bladder. VALSTAR was removed from the ...
... Extracranial Resources Benefits Baltimore ... Area and ... Cancer Center at Johns Hopkins Medicine is adding an Elekta,Synergy(R) S ... Johns Hopkins aims to fight cancer with,both intracranial and extracranial resources ...
... Balance of Year, SAN DIEGO, Aug. 17 ... Noble Financial Equity,Conference at 11:30 a.m. EDT on Tuesday, ... South Carolina. William Spencer, Imagenetix,s Chief Executive Officer ... and prospects for the,Company. Commenting on the prospects, Mr. ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 2Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 3Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007 2
(Date:9/2/2014)... hot oven, you rapidly pull your hand away. Although ... and responding to such painful stimuli, they are still ... made a surprising discovery about the role of a ... built a structural model of the molecule. These discoveries, ... help direct new strategies to treat pain in people. ...
(Date:9/1/2014)... of research shows an association between TV viewing and ... a new Cornell University study points out that not ... people to eat twice as much as other programs! ... while snacking your mouth will see more action too!" ... article just published in the Journal of the ...
(Date:9/1/2014)... of the U.S. diet showed some modest improvement in ... reduction in the consumption of unhealthy trans fats, but ... rich and the poor. , , An unhealthy diet ... cancers. Eating a healthy diet is an important part ... population trends in diet quality is important because it ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Can action movies make you fat? 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... picture in this kind of article , A detailed ... in activating the Epstein Barr Virus in human cells has ... Laboratory (EMBL) and the Institut de Virologie Moléculaire et Structurale ... in Grenoble. , Like Sleeping Beauty, the Epstein Barr Virus ...
... leading plant science centre have uncovered a gene that could ... able to cope with the changing world climate. Researchers funded ... the John Innes Centre in Norwich have identified the gene ... changes in the length of the day. This is key ...
... avian flu conference last fall believe there is little chance ... enough vaccine or antiviral medication to stop a bird flu ... be spread easily from human to human, according to a ... of the survey will be published in the June 2006 ...
Cached Biology News:Waking a sleeping virus 2Growing crops to cope with climate change 2Medical experts: US unlikely to have enough vaccines to stop avian flu 2